Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Joost B Koedijk"'
Autor:
Farnaz Barneh, Joost B. Koedijk, Noa E. Wijnen, Tom Meulendijks, Minoo Ashtiani, Ester Dunnebach, Noël Dautzenberg, Annelisa M. Cornel, Anja Krippner-Heidenreich, Kim Klein, Michel C. Zwaan, Jürgen Kuball, Stefan Nierkens, Jacqueline Cloos, Gertjan J.L. Kaspers, Olaf Heidenreich
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/cff2ded88b614bbb83ba79f4ca97beae
Autor:
Joost B. Koedijk, Thomas B. van Beek, Marijn A. Vermeulen, Lennart A. Kester, Elizabeth K. Schweighart, Stefan Nierkens, Mirjam E. Belderbos, C. Michel Zwaan, Katja M. J. Heitink-Pollé, Olaf Heidenreich
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Regression of leukemia in the absence of disease-modifying therapy remains poorly understood, although immunological mechanisms are thought to play a role. Here, we present a unique case of a 17-year-old boy with immune dysregulation and long-lasting
Externí odkaz:
https://doaj.org/article/b1ef9090fbca46babb653538dcd1bab1
Autor:
Noa E Wijnen, Joost B Koedijk, Kim Klein, Maaike Luesink, Bianca F Goemans, C Michel Zwaan, Gertjan JL Kaspers
Publikováno v:
Wijnen, N E, Koedijk, J B, Klein, K, Luesink, M, Goemans, B F, Zwaan, C M & Kaspers, G J L 2023, ' Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients : Focus on the Clinical Value of Gemtuzumab Ozogamicin ', OncoTargets and Therapy, vol. 16, pp. 297-308 . https://doi.org/10.2147/OTT.S263829
Although survival in pediatric acute myeloid leukemia (AML) has increased considerably over the past decades, refractory disease and relapse rates remain high. Refractory and relapsed disease are difficult to treat, with overall survival rates less t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e89900c44faa3ba6908598a7169738d
http://www.scopus.com/inward/record.url?scp=85159358897&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85159358897&partnerID=8YFLogxK
Autor:
Joost B. Koedijk, Inge van der Werf, Marijn A. Vermeulen, Alicia Perzolli, Marta Fiocco, Hester A. de Groot-Kruseman, Rubina Moeniralam, Stefan Nierkens, Mirjam E. Belderbos, C. Michel Zwaan, Olaf Heidenreich
Pediatric cancers are characterized by a relatively low mutational burden and therefore, children are thought to be poor candidates for T cell-engaging immunotherapies. Here, we performed a multidimensional characterization of the tumor immune microe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc67c90206be9a5cd7841f3a964695f6
https://doi.org/10.1101/2023.03.03.23286485
https://doi.org/10.1101/2023.03.03.23286485
Autor:
Inge van der Werf, Gertjan J.L. Kaspers, Olaf Heidenreich, Friso G. Calkoen, Christian M. Zwaan, Stefan Nierkens, Joost B. Koedijk
Publikováno v:
Cancers, Vol 13, Iss 4364, p 4364 (2021)
Koedijk, J B, van der Werf, I, Calkoen, F G, Nierkens, S, Kaspers, G J L, Zwaan, C M & Heidenreich, O 2021, ' Paving the way for immunotherapy in pediatric acute myeloid leukemia : Current knowledge and the way forward ', Cancers, vol. 13, no. 17, 4364 . https://doi.org/10.3390/cancers13174364
Cancers
Koedijk, J B, van der Werf, I, Calkoen, F G, Nierkens, S, Kaspers, G J L, Zwaan, C M & Heidenreich, O 2021, ' Paving the way for immunotherapy in pediatric acute myeloid leukemia : Current knowledge and the way forward ', Cancers, vol. 13, no. 17, 4364 . https://doi.org/10.3390/cancers13174364
Cancers
Simple Summary Immunotherapy may be an attractive treatment option to increase survival, and to reduce treatment-related side effects, for children with acute myeloid leukemia (AML). While immunotherapies have shown successes in many cancer types, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9747312546f024d40f93c11fbda34f8
https://doi.org/10.3390/cancers13174364
https://doi.org/10.3390/cancers13174364
Autor:
Joost B. Koedijk, Daan J Touw, C.G.H. Valk-Swinkels, Nils E. van 't Veer, Paul G.H. Mulder, Nardo J. M. van der Meer, Peter H. J. van der Voort, Tom A. Rijpstra
Publikováno v:
Antimicrobial Agents and Chemotherapy, 60(6), 3587-3590. AMER SOC MICROBIOLOGY
The objective of this study was to describe the pharmacokinetics of cefotaxime (CTX) in critically ill patients with acute kidney injury (AKI) when treated with continuous renal replacement therapy (CRRT) in the intensive care unit (ICU). This single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0149908adf96a5663c7c6705f9334cc4
https://doi.org/10.1128/aac.02888-15
https://doi.org/10.1128/aac.02888-15